Evotec SE
Company Profile
Business description
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Contact
Essener Bogen 7
Manfred Eigen Campus
Hamburg22419
DEUT: +49 40560810
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
5,022
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,157.90 | 0.80 | -0.01% |
CAC 40 | 8,087.12 | 44.17 | 0.55% |
DAX 40 | 23,044.60 | 152.92 | 0.67% |
Dow JONES (US) | 41,985.35 | 32.03 | 0.08% |
FTSE 100 | 8,689.16 | 42.37 | 0.49% |
HKSE | 23,905.56 | 215.84 | 0.91% |
NASDAQ | 17,784.05 | 92.42 | 0.52% |
Nikkei 225 | 37,608.49 | 68.57 | -0.18% |
NZX 50 Index | 12,128.21 | 14.67 | 0.12% |
S&P 500 | 5,667.56 | 4.67 | 0.08% |
S&P/ASX 200 | 7,936.90 | 5.70 | 0.07% |
SSE Composite Index | 3,370.03 | 5.20 | 0.15% |